Does 0102U require prior authorization?

No, 0102U does not require prior authorization (high confidence). Code is covered without prior authorization.

`0102U`

HCPCS/CPT

No Prior Auth Required

Code is covered without prior authorization (high confidence)

The article does not specify documentation requirements; follow the documentation, medical record, and prior authorization requirements described in LCD MolDX: Repeat Germline Testing L38429 and MolDX program guidance.
This article provides billing and coding guidelines that complement the Local Coverage Determination (LCD) MolDX: Repeat Germline Testing L38288 and refers providers/claimants to LCD L38288 for detailed coverage criteria.
Claims for repeat germline testing must reference and be supported by documentation consistent with MolDX LCD L38351, including prior germline test reports and clinical rationale for repeat testing.
Follow applicable billing/coding instructions and any required forms or prior authorization processes specified by the LCD or local Medicare Administrative Contractor.

Coverage for repeat germline testing is determined by the referenced Local Coverage Determination MolDX: Repeat Germline Testing L38429; consult that LCD for specific clinical indications that constitute covered testing.
Repeat germline testing is covered when it meets the clinical and coverage criteria specified in the MolDX Local Coverage Determination L38351.
To report a Molecular Diagnostic Test (MDT) service, submit the appropriate CPT code, include the appropriate DEX Z-Code identifier adjacent to the CPT code in the claim comment/narrative field, and enter 1 unit of service (UOS).
Lab-developed tests for inherited cancer syndromes in patients with cancer (per LCD L38966) are covered when billed with the required claim elements specified in this policy.
Coverage applies for lab-developed tests (LDTs) for inherited cancer syndromes in patients with cancer when billed in accordance with MolDX LCD L38972.
Lab-developed tests for inherited cancer syndromes in patients with cancer are billed per this guidance and the referenced LCD L38974.

A58756 — Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer

J05

L39040 — MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer

J05

A57772 — Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT)

J05

L36807 — MolDX: Molecular Diagnostic Tests (MDT)

J05

Ask Verity about documentation requirements, denial risks, or coverage in your state.